(CCCC) C4 Therapeutics - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 426m USD | Total Return: 154.6% in 12m
Avg Turnover: 7.69M
Qual. Beats: 0
Rev. Trend: 83.8%
Qual. Beats: 0
Warnings
Share dilution 78.0% YoY
Altman Z'' -2.93 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Tailwind, Pullback Swing, Confidence
C4 Therapeutics (CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), a therapeutic modality that utilizes the body’s natural protein disposal system to eliminate disease-causing proteins. Based in Watertown, Massachusetts, the company’s pipeline includes Cemsidomide, an oral degrader targeting IKZF1/3 for multiple myeloma, and CFT8919, an allosteric degrader for EGFR-mutant non-small cell lung cancer. Unlike traditional inhibitors that merely block protein function, TPD technology aims to remove the protein entirely, potentially overcoming common drug resistance mechanisms.
The company operates through a partnership-heavy business model, maintaining strategic collaborations with major pharmaceutical entities including Roche, Merck KGaA, and Betta Pharmaceuticals. These agreements often involve the development of Degrader-Antibody Conjugates, which combine the specificity of antibodies with the potency of protein degraders to target cancer cells more precisely. Within the high-risk biotechnology sector, such collaborations are critical for offseting research and development costs while validating the underlying platform technology.
For a detailed analysis of the companys valuation metrics and institutional ownership trends, visit ValueRay. C4 Therapeutics remains focused on expanding its portfolio into inflammation and neurodegeneration as it advances its primary oncology candidates through clinical trials.
- Cemsidomide phase 2 clinical data readouts for multiple myeloma treatment
- CFT8919 development milestones in EGFR mutant non-small cell lung cancer
- Strategic collaboration revenue and milestone payments from Roche and Merck
- R&D expenditure levels impacting cash runway and future equity financing
- Regulatory approval pathways for novel protein degrader and antibody conjugate platforms
| Net Income: -103.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA -2.62 > 1.0 |
| NWC/Revenue: 625.7% < 20% (prev 481.9%; Δ 143.8% < -1%) |
| CFO/TA -0.29 > 3% & CFO -95.4m > Net Income -103.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (126.1m) vs 12m ago 77.99% < -2% |
| Gross Margin: 77.12% > 18% (prev 80.19%; Δ -3.07% > 0.5%) |
| Asset Turnover: 10.75% > 50% (prev 12.45%; Δ -1.70% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.66 (Total Current Assets 245.4m - Total Current Liabilities 27.2m) / Total Assets 328.9m |
| B: -2.32 (Retained Earnings -763.8m / Total Assets 328.9m) |
| C: -0.34 (EBIT TTM -111.6m / Avg Total Assets 324.2m) |
| D: 2.48 (Book Value of Equity 234.2m / Total Liabilities 94.6m) |
| Altman-Z'' = -2.93 = D |
| DSRI: 0.41 (Receivables 2.88m/8.03m, Revenue 34.9m/39.8m) |
| GMI: 1.04 (GM 80.19% / 77.12%) |
| AQI: 1.51 (AQ_t 0.12 / AQ_t-1 0.08) |
| SGI: 0.88 (Revenue 34.9m / 39.8m) |
| TATA: -0.03 (NI -103.8m - CFO -95.4m) / TA 328.9m) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of June 12, 2026, the stock is trading at USD 3.87 with a total of 2,226,394 shares traded.
Over the past week, the price has changed by -7.19%,
over one month by +22.08%,
over three months by +29.43% and
over the past year by +154.61%.
C4 Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CCCC.
- StrongBuy: 4
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.3 | 217.6% |
P/S = 12.2109
P/B = 1.9659
Revenue TTM = 34.9m USD
EBIT TTM = -111.6m USD
EBITDA TTM = -108.3m USD
Long Term Debt = 51.9m USD (estimated: total debt 58.4m - short term 6.52m)
Short Term Debt = 6.52m USD (from shortTermDebt, last quarter)
Debt = 58.4m USD (from shortLongTermDebtTotal, last quarter) (leases 58.4m already included)
Net Debt = -177.2m USD (calculated: Debt 58.4m - CCE 235.7m)
Enterprise Value = 248.5m USD (425.7m + Debt 58.4m - CCE 235.7m)
Interest Coverage Ratio = unknown (Ebit TTM -111.6m / Interest Expense TTM 0.0)
EV/FCF = -2.98x (Enterprise Value 248.5m / FCF TTM -83.4m)
FCF Yield = -33.58% (FCF TTM -83.4m / Enterprise Value 248.5m)
FCF Margin = -239.3% (FCF TTM -83.4m / Revenue TTM 34.9m)
Net Margin = -297.8% (Net Income TTM -103.8m / Revenue TTM 34.9m)
Gross Margin = 77.12% ((Revenue TTM 34.9m - Cost of Revenue TTM 7.97m) / Revenue TTM)
Gross Margin QoQ = 70.72% (prev 83.61%)
Tobins Q-Ratio = 0.76 (Enterprise Value 248.5m / Total Assets 328.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 58.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -88.2m (EBIT -111.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.76 (Total Current Assets 245.4m / Total Current Liabilities 28.0m)
Debt / Equity = 0.25 (Debt 58.4m / totalStockholderEquity, last quarter 234.2m)
Debt / EBITDA = 1.64 (negative EBITDA) (Net Debt -177.2m / EBITDA -108.3m)
Debt / FCF = 2.12 (negative FCF - burning cash) (Net Debt -177.2m / FCF TTM -83.4m)
Total Stockholder Equity = 204.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.02% (Net Income -103.8m / Total Assets 328.9m)
RoE = -50.68% (Net Income TTM -103.8m / Total Stockholder Equity 204.8m)
RoCE = -43.46% (EBIT -111.6m / Capital Employed (Equity 204.8m + L.T.Debt 51.9m))
RoIC = -28.77% (negative operating profit) (NOPAT -88.2m / Invested Capital 306.4m)
WACC = 13.40% (E(425.7m)/V(484.1m) * Re(15.24%) + D(58.4m)/V(484.1m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 15.24% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 49.24%
[DCF] Fair Price = unknown (Cash Flow -83.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.82 | # QB: 0
Revenue Correlation: 83.79 | Revenue CAGR: 32.12% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.24 | Chg30d=+18.64% | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.27 | Chg30d=+9.59% | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=-0.99 | Chg30d=+11.24% | Revisions=+0% | GrowthEPS=+13.2% | GrowthRev=-46.1%
EPS next Year (2027-12-31): EPS=-1.16 | Chg30d=+8.13% | Revisions=+0% | GrowthEPS=-17.2% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: +20%